Protease-Activated Receptor 2 in inflammatory skin disease: current evidence and future perspectives

Protease-activated receptor-2 (PAR2) is a class-A G protein-coupled receptor (GPCR) activated by serine proteases and is expressed by multiple tissues, including the skin. PAR2 is involved in the skin inflammatory response, promoting Th2 inflammation, delaying skin barrier repair, and affecting the differentiation of keratinocytes. It also participates in the transmission of itch and pain sensations in the skin. Increasing evidence indicates that PAR2 plays an important role in the pathogenesis of inflammatory skin diseases such as acne vulgaris, rosacea, psoriasis, and atopic dermatitis. Additional focus will be placed on potential targeted therapies based on PAR2. The Goal of this review is to outline the emerging effects of PAR2 activation in inflammatory skin disease and highlight the promise of PAR2 modulators.

• Publication year

  2024

• Venue

  Frontiers in Immunology

• Publication date

  2024-09-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.3389/fimmu.2024.1448952PMID 39301020PMCID 11410643
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neuronal BST2: A Pruritic Mediator Alongside PAR2 in the Interleukin-27-Driven Itch Pathway.

  2024cited by this paper
• Blockade of Proteinase-Activated Receptor 2 (PAR2) Attenuates Neuroinflammation in Experimental Autoimmune Encephalomyelitis

  2023cited by this paper
• FSLLRY-NH2, a protease-activated receptor 2 (PAR2) antagonist, activates mas-related G protein-coupled receptor C11 (MrgprC11) to induce scratching behaviors in mice.

  2023cited by this paper
• Protease-Activated Receptor-2 and Phospholipid Metabolism Analysis in Hyperuricemia-Induced Renal Injury

  2023cited by this paper
• The Yin‐Yang roles of protease‐activated receptors in inflammatory signalling and diseases

  2022cited by this paper
• C781, a β-Arrestin Biased Antagonist at Protease-Activated Receptor-2 (PAR2), Displays in vivo Efficacy Against Protease-Induced Pain in Mice

  2022cited by this paper
• GB83, an Agonist of PAR2 with a Unique Mechanism of Action Distinct from Trypsin and PAR2-AP

  2022cited by this paper
• β‐Arrestin‐biased proteinase‐activated receptor‐2 antagonist C781 limits allergen‐induced airway hyperresponsiveness and inflammation

  2022cited by this paper
• Mast cell tryptase enhances wound healing by promoting migration in human bronchial epithelial cells

  2021cited by this paper
• Protease-Activated Receptor 2 (PAR-2) Antagonist AZ3451 Mitigates Oxidized Low-Density Lipoprotein (Ox-LDL)-Induced Damage and Endothelial Inflammation.

  2021cited by this paper
• Proteinase‐activated receptor‐2 antagonist C391 inhibits Alternaria‐induced airway epithelial signalling and asthma indicators in acute exposure mouse models

  2021cited by this paper
• Proteinase-Mediated Macrophage Signaling in Psoriatic Arthritis

  2021cited by this paper
• Blockade of protease-activated receptor 2 attenuates allergen-mediated acute lung inflammation and leukocyte recruitment in mice

  2021cited by this paper
• Rosacea: New Concepts in Classification and Treatment

  2021cited by this paper
• A positive feedback loop between mTORC1 and cathelicidin promotes skin inflammation in rosacea

  2021cited by this paper
• Protease-activated receptor 2 induces ROS-mediated inflammation through Akt-mediated NF-κB and FoxO6 modulation during skin photoaging

  2021cited by this paper
• Protease-Activated Receptor-2 Regulates Neuro-Epidermal Communication in Atopic Dermatitis

  2020cited by this paper
• Protease-activated receptor-2 ligands reveal orthosteric and allosteric mechanisms of receptor inhibition

  2020cited by this paper
• The PAR2 inhibitor I-287 selectively targets Gαq and Gα12/13 signaling and has anti-inflammatory effects

  2020cited by this paper
• The development of proteinase-activated receptor-2 modulators and the challenges involved

  2020cited by this paper
• Blockage of protease-activated receptor 2 exacerbates inflammation in high-fat environment partly through autophagy inhibition.

  2020cited by this paper
• Targeting of protease activator receptor-2 (PAR-2) antagonist FSLLRY-NH2 as an asthma adjuvant therapy

  2020cited by this paper
• Soluble Dipeptidyl Peptidase-4 Induces Fibroblast Activation Through Proteinase-Activated Receptor-2

  2020cited by this paper
• Mast Cell Tryptase Promotes Inflammatory Bowel Disease-Induced Intestinal Fibrosis.

  2020cited by this paper
• Multifaceted Analyses of Epidermal Serine Protease Activity in Patients with Atopic Dermatitis

  2020cited by this paper
• PAR2 mediates itch via TRPV3 signaling in keratinocytes.

  2020cited by this paper
• Comel‐Netherton syndrome: A local skin barrier defect in the absence of an underlying systemic immunodeficiency

  2020cited by this paper
• Topical 10% Tranexamic acid for erythematotelangiectatic steriod induced rosacea.

  2020cited by this paper
• Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis

  2020cited by this paper
• Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases

  2019cited by this paper
• Thrombin cleaves and activates the protease-activated receptor 2 dependent on thrombomodulin co-receptor availability

  2019cited by this paper
• Decreased level of PAR2 in Psoriasis and MF patients receiving Phototherapy

  2019cited by this paper
• PAR2 Pepducin-Based Suppression of Inflammation and Itch in Atopic Dermatitis Models.

  2019cited by this paper
• Protease-activated receptor 2 (PAR-2) antagonist AZ3451 as a novel therapeutic agent for osteoarthritis

  2019cited by this paper
• Update on protease‐activated receptor 2 in cutaneous barrier, differentiation, tumorigenesis and pigmentation, and its role in related dermatologic diseases

  2019cited by this paper
• Abstract 449: Pepducin Inhibition of Protease-activated Receptor 2 Attenuates a Mouse Model of Abdominal Aortic Aneurysm

  2019cited by this paper
• New mechanism underlying IL‐31–induced atopic dermatitis

  2018cited by this paper
• Cutibacterium acnes (Propionibacterium acnes) and acne vulgaris: a brief look at the latest updates

  2018cited by this paper
• Activation of protease-activated receptor 2 leads to impairment of keratinocyte tight junction integrity.

  2018cited by this paper
• Design and Evaluation of Heterobivalent PAR1-PAR2 Ligands as Antagonists of Calcium Mobilization.

  2018cited by this paper
• Systemic sclerosis.

  2017cited by this paper
• Inhibitory effect of FSLLRY-NH2 on inflammatory responses induced by hydrogen peroxide in HepG2 cells

  2017cited by this paper
• Structural insight into allosteric modulation of protease-activated receptor 2

  2017cited by this paper
• A T cell-specific knockout reveals an important role for protease-activated receptor 2 in lymphocyte development.

  2017cited by this paper
• Systemic sclerosis

  2017cited by this paper
• Targeting Liver Fibrosis with a Cell-penetrating Protease-activated Receptor-2 (PAR2) Pepducin*

  2016cited by this paper
• Protease activated receptor 2 (PAR2) modulators: a patent review (2010–2015)

  2016cited by this paper
• Blocking proteinase-activated receptor 2 alleviated neuropathic pain evoked by spinal cord injury.

  2016cited by this paper
• Topical tranexamic acid improves the permeability barrier in rosacea

  2015cited by this paper
• Protease-Activated Receptor-2 Is Associated with Terminal Differentiation of Epidermis and Eccrine Sweat Glands

  2015cited by this paper
• Functional inhibition of PAR2 alleviates allergen‐induced airway hyperresponsiveness and inflammation

  2015cited by this paper
• Expression of Protease-Activated Receptor-2 in SZ95 Sebocytes and its Role in Sebaceous Lipogenesis, Inflammation, and Innate Immunity.

  2015cited by this paper
• Expression of Protease-Activated Receptor-2 in SZ95 Sebocytes and its Role in Sebaceous Lipogenesis, Inflammation, and Innate Immunity.

  2015cited by this paper
• Cathepsin S, a new pruritus biomarker in clinical dandruff/seborrhoeic dermatitis evaluation

  2014cited by this paper
• Increased Expression of Cathelicidin by Direct Activation of Protease-Activated Receptor 2: Possible Implications on the Pathogenesis of Rosacea

  2014cited by this paper
• Soluble DPP4 induces inflammation and proliferation of human smooth muscle cells via protease-activated receptor 2.

  2014cited by this paper
• β-arrestins and G protein-coupled receptor trafficking.

  2014cited by this paper
• Pathway‐selective antagonism of proteinase activated receptor 2

  2014cited by this paper
• Transactivation of the PAR1-PAR2 Heterodimer by Thrombin Elicits β-Arrestin-mediated Endosomal Signaling*

  2013cited by this paper
• Pharmacological inhibition of PAR2 with the pepducin P2pal-18S protects mice against acute experimental biliary pancreatitis.

  2013cited by this paper
• β-Arrestin-2 mediates the proinflammatory effects of proteinase-activated receptor-2 in the airway

  2012cited by this paper
• Protease-activated receptor-2 (PAR2) mediates VEGF production through the ERK1/2 pathway in human glioblastoma cell lines.

  2012cited by this paper
• Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110)

  2012cited by this paper
• Role of protease‐activated receptors in human skin fibrosis and scleroderma

  2011cited by this paper
• Interdicting protease-activated receptor-2-driven inflammation with cell-penetrating pepducins

  2011cited by this paper
• Fully human antibodies against the Protease-Activated Receptor-2 (PAR-2) with anti-inflammatory activity

  2011cited by this paper
• Involvement of ERK1/2/NF-κB signal transduction pathway in TF/FVIIa/PAR2-induced proliferation and migration of colon cancer cell SW620

  2011cited by this paper
• Protease-activated receptor 2 signaling in inflammation

  2011cited by this paper
• PAR2 absence completely rescues inflammation and ichthyosis caused by altered CAP1/Prss8 expression in mouse skin

  2011cited by this paper
• Protease-activated receptor-2 mediates the expression of inflammatory cytokines, antimicrobial peptides, and matrix metalloproteinases in keratinocytes in response to Propionibacterium acnes

  2010cited by this paper
• Elastase 2 is expressed in human and mouse epidermis and impairs skin barrier function in Netherton syndrome through filaggrin and lipid misprocessing.

  2010cited by this paper
• Novel agonists and antagonists for human protease activated receptor 2.

  2010cited by this paper
• Protease and Protease-Activated Receptor-2 Signaling in the Pathogenesis of Atopic Dermatitis

  2010cited by this paper
• Increased mast cell expression of PAR‐2 in skin inflammatory diseases and release of IL‐8 upon PAR‐2 activation

  2010cited by this paper
• Par2 inactivation inhibits early production of TSLP, but not cutaneous inflammation, in Netherton syndrome adult mouse model.

  2010cited by this paper
• Involvement of Tryptase and Proteinase-Activated Receptor-2 in Spontaneous Itch-Associated Response in Mice With Atopy-like Dermatitis.

  2009cited by this paper
• THEMED ISSUE: GPCR RESEARCH PAPER Novel antagonists for proteinase-activated receptor 2: inhibition of cellular and vascular responses in vitro and in vivo

  2009cited by this paper
• Agonist-Biased Signaling via Proteinase Activated Receptor-2: Differential Activation of Calcium and Mitogen-Activated Protein Kinase Pathways

  2009cited by this paper
• Dual effect of the novel peptide antagonist K‐14585 on proteinase‐activated receptor‐2‐mediated signalling

  2009cited by this paper
• Tetracyclines Modulate Protease-Activated Receptor 2-Mediated Proinflammatory Reactions in Epidermal Keratinocytes

  2009cited by this paper
• Mite serine protease activates protease‐activated receptor‐2 and induces cytokine release in human keratinocytes

  2009cited by this paper
• Kallikrein 5 induces atopic dermatitis–like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome

  2009cited by this paper
• Participation of proteinase-activated receptor-2 in passive cutaneous anaphylaxis-induced scratching behavior and the inhibitory effect of tacrolimus.

  2009cited by this paper
• Acute modulations in permeability barrier function regulate epidermal cornification: role of caspase-14 and the protease-activated receptor type 2.

  2008cited by this paper
• Proteinase-activated receptor-2 in the skin: receptor expression, activation and function during health and disease.

  2008cited by this paper
• Mite and cockroach allergens activate protease-activated receptor 2 and delay epidermal permeability barrier recovery.

  2008influential reference
• Activation of proteinase-activated receptor-2 by human kallikrein-related peptidases.

  2008cited by this paper
• Effect of 14-Membered-Ring Macrolides on Production of Interleukin-8 Mediated by Protease-Activated Receptor 2 in Human Keratinocytes

  2008cited by this paper
• Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin.

  2008cited by this paper
• Physiological research.

  2008cited by this paper
• Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells

  2007cited by this paper
• Pathogenesis and clinical features of psoriasis.

  2007cited by this paper
• Kallikrein 8 Is Involved in Skin Desquamation in Cooperation with Other Kallikreins*

  2007cited by this paper
• Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea

  2007cited by this paper
• Cytokine upregulation of proteinase‐activated‐receptors 2 and 4 expression mediated by p38 MAP kinase and inhibitory kappa B kinase β in human endothelial cells

  2007cited by this paper
• Protease-activated receptor 2 mediates the proinflammatory effects of synovial mast cells.

  2007cited by this paper
• Serine protease signaling of epidermal permeability barrier homeostasis.

  2006influential reference
• Therapeutic Promise of Proteinase-Activated Receptor-2 Antagonism in Joint Inflammation

  2006cited by this paper
• A major role for proteolytic activity and proteinase-activated receptor-2 in the pathogenesis of infectious colitis.

  2005cited by this paper
• Human airway trypsin-like protease induces PAR-2-mediated IL-8 release in psoriasis vulgaris.

  2004cited by this paper

• Dysregulated proteolytic cascades in Netherton syndrome: from molecular pathology to preclinical drug testing

  2026cites this paper
• Innovative Skin Depigmenting Strategies: A Review

  2026cites this paper
• Integrated Methylome-Transcriptome Analysis Reveals Epigenomic Remodeling and Rho GTPase-Linked Immune-Epithelial Crosstalk in Atopic Dermatitis.

  2026cites this paper
• Mast Cells Promote Macrophage Polarization to M1-like Phenotype through a Tryptase-dependent Process

  2025cites this paper
• The Binding and Effects of Boron-Containing Compounds on G Protein-Coupled Receptors: A Scoping Review

  2025cites this paper
• Host–Microbiome Interactions in Chronic Itch

  2025cites this paper
• Design of cathepsin-sensitive linkers for tumor-selective bioconjugate drug delivery.

  2025cites this paper
• A New Strategy in Modulating the Protease-Activated Receptor 2 (Par2) in Autoimmune Diseases

  2025cites this paper
• Plasma Kallikrein Inhibitors for Multiple Disorders: Current Advances and Perspectives.

  2025cites this paper
• Functional and Morphological Plasticity of the Endolysosomal System: Pigment Organelles at the Crossroads of Physiology and Pathology

  2025cites this paper
• The potential link between soybean oil-induced lipotoxicity and vitiligo: A review

  2025cites this paper
• CD Molecules Nomenclature 2025: Antibody Validation and Expression Profiling of Immune System G Protein‐Coupled Receptors

  2025influential citation
• Blockade of PAR2 Signaling by Punicalagin as a Therapeutic Strategy for Atopic Dermatitis

  2025cites this paper
• Chronic inflammatory skin disorders: understanding pathophysiology and therapeutic challenges

  2025cites this paper
• Topical administration of coumarin derivatives alleviates skin inflammatory symptoms in atopic dermatitis model.

  2025cites this paper